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Abstract
We sought to investigate the relationship between blood–brain barrier (BBB) permeability and microstructural white
matter integrity, and their potential impact on long-term functional outcomes in patients with acute ischemic stroke (AIS).
We studied 184 AIS subjects with perfusion-weighted MRI (PWI) performed<9 h from last known well time. White matter
hyperintensity (WMH), acute infarct, and PWI-derived mean transit time lesion volumes were calculated. Mean BBB
leakage rates (K2 coefficient) and mean diffusivity values were measured in contralesional normal-appearing white
matter (NAWM). Plasma matrix metalloproteinase-2 (MMP-2) levels were studied at baseline and 48 h. Admission
stroke severity was evaluated using the NIH Stroke Scale (NIHSS). Modified Rankin Scale (mRS) was obtained at
90-days post-stroke. We found that higher mean K2 and diffusivity values correlated with age, elevated baseline MMP-2
levels, greater NIHSS and worse 90-day mRS (all p< 0.05). In multivariable analysis, WMH volume was associated with
mean K2 (p¼ 0.0007) and diffusivity (p¼ 0.006) values in contralesional NAWM. In summary, WMH severity measured
on brain MRI of AIS patients is associated with metrics of increased BBB permeability and abnormal white matter
microstructural integrity. In future studies, these MRI markers of diffuse cerebral microvascular dysfunction may improve
prediction of cerebral tissue infarction and functional post-stroke outcomes.
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Introduction
Diffuse cerebral small vessel disease detected on
T2-weighted MRI as white matter hyperintensity
(WMH) or leukoaraiosis is a common finding that is
strongly linked to functional decline in aging adults and
to poor stroke outcomes.1–3 Although risk factors such
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as advanced age, hypertension, hyperhomocysteinemia,
and smoking have been associated with WMH, vari-
ability in WMH severity is largely unexplained, and
its pathophysiology remains elusive.4 Chronic hypoper-
fusion has been proposed as one underlying mechanism
of WMH progression, as subcortical white matter is
characterized by regions of terminal circulation with
poor or absent collateral flow, and patients with
increased WMH burden have impaired cerebrovascular
reactivity and reduced periventricular cerebral blood
flow (CBF).5–7
Another hypothesis is that vascular risk factors may
induce progressive chronic endothelial injury, disrupt-
ing the blood–brain barrier (BBB) and leading to
parenchymal accumulation of blood constituents that
are potentially neurotoxic.8,9 One potential mechanism
implicated in this process is linked to matrix metallo-
proteinase-2 (MMP-2), an enzyme known for its role in
chronic BBB remodeling, which is activated by
hypoxia-inducible factor 1 (HIF-1) early during an
acute cerebral ischemic event.10,11 Prior studies have
shown that WMH volume (WMHv) is associated with
circulating plasma MMP-2 levels in patients with acute
ischemic stroke (AIS);12 however, it is not clear whether
the elevated MMP-2 levels directly translate to detect-
able BBB disruption. One radiographic approach to
evaluate microvascular BBB disruption is to measure
the effects of leakage of contrast agent (i.e., ‘‘K2 coef-
ficient’’) to extravascular space.13
If the association between BBB integrity, circulating
MMP-2 levels, and WMH severity is confirmed, this
study may suggest a plausible underlying biological
mechanism that links WMH burden and BBB perme-
ability. Because changes in diffusivity of water molecules
have been suggested to be precursors of eventual WMH
development on FLAIR,14 we will also investigate the
association between BBB permeability and diffusivity.
To test the hypothesis thatWMHseverity is associated
with increasing BBB permeability, as a measure of diffuse
microvascular dysfunction, and that circulating levels of
MMP-2 are correlated with the MRI markers of white
matter structural integrity, we sought to: (1) examine the
relationship between BBB permeability and microstruc-
tural white matter integrity in normal-appearing white
matter (NAWM), as measured by K2 coefficients and
apparent diffusivity coefficients (ADC), respectively,
and (2) investigate their association with degree of acute
cerebral tissue injury and long-term functional outcomes.
Materials and methods
Subjects
The study was approved by the Partners Human
Research Committee (protocol # 2011P002725), which
operates in compliance with all applicable regulations
and guidelines pertaining to Institutional Review
Boards as follows: Department of Health and Human
Services (DHHS) 45 CFR Parts 46 and 164, Food and
Drug Administration (FDA) 21 CFR Parts 50 and 56
and International Conference on Harmonization (ICH)
guidance relating to Good Clinical Practice (GCP),
section 3 (3.1–3.4) unless ICH guidelines conflict with
FDA Regulations. All participating subjects or their
surrogates provided informed consent. We retrospect-
ively analyzed data from a prospective cohort of con-
secutive adult (age 18 years) AIS patients admitted to
our institution from February 2007 to February 2011 as
part of an observational NIH Specialized Program of
Translational Research in Acute Stroke (SPOTRIAS)
study.12
All patients presenting to two participating academic
medical centers within 9h of last known well (LKW)
time were eligible. For all consented subjects, data
were acquired through medical record review or in-
person interviews. Baseline clinical characteristics were
obtained on admission. For this study, patients were
included if they met the following criteria: (a) MRI per-
formed at admission (<9h from LKW) that included
diffusion-weighted MRI (DWI), dynamic susceptibility
contrast-enhanced (DSC) perfusion-weighted MRI
(PWI), and T2-weighted fluid-attenuated inversion
recovery (FLAIR) MRI; (b) evidence of a confirmed
acute infarct on DWI; and (c) plasma MMP-2 levels
collected at the time of enrollment.
Matrix metalloproteinase-2 analysis
Plasma samples were collected twice: in the acute phase
(less than 9 h after stroke onset) and at 48 h (36–60 h
after stroke onset). Samples were drawn in ethylene-
diaminetetraacetic acid tubes, using a butterfly needle
to reduce shear stress, placed on ice and immediately
centrifuged at 3000 revolutions per minutes for 15min.
Plasma was subsequently isolated and frozen at 80C
for later measurement. Levels of MMP-2 were analyzed
using a commercially available enzyme-linked immuno-
sorbent assay (ELISA) (R&D systems) and expressed in
nanograms per milliliter (ng/mL). ELISA was per-
formed according to the manufacturer’s instructions
by investigators (K.A., E.H.L.) blinded to clinical and
imaging information.
Imaging analysis
MRI data acquisition. All MRI was performed on 1.5T
General Electric scanners with the exception of three
studies that were acquired on a 3T Siemens system.
For 10 cases, FLAIR scans were acquired on a different
scan date from the DWI and PWI scans due to
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unusable or unavailable FLAIR scans. For the major-
ity of the subjects, axial T2-weighted FLAIR MRI was
acquired with TR/TE/TI¼ 10002/145/2200ms, 220mm
field-of-view (FOV), 5mm slice thickness with 1mm
gap, and in-plane resolution of 0.86 0.86mm2.
Diffusion tensor imaging (DTI) was acquired using
echo-planar imaging (EPI) with the following param-
eters for the majority of the cases: TR/TE¼ 5000/
85.3ms, 220mm FOV, 5-mm slice thickness with
1-mm gap, in-plane resolution of 0.86 0.86mm2
(128 128 acquisition matrix up-sampled to
256 256), three 0 s/mm2 (b-zero) and 1000 s/mm2
b-values in 25 directions. DTI datasets were corrected
for motion and eddy current distortions.15 ADC
maps were derived mathematically from the high- and
low-b-value images.15
PWI was performed using serial acquisition of
gradient-echo EPI T2*-weighted images. Images were
acquired before and during power injection of a gado-
linium-based contrast agent. The imaging protocol con-
sisted of 80 acquisitions at a TR/TE¼ 1500/40ms,
220mm FOV, 5mm slice thickness with 1mm gap,
1.72 1.72mm2 in plane resolution for most of the
cases. K2 coefficients (s1) were derived from the con-
centration-time curves using the Boxerman-Weisskoff
model and techniques previously described.13 In
brief, the measured concentration-time curve can be
modeled as
 R2 tð Þ  K1 R






where R2 tð Þ is the true concentration, and solve for K2
using a linear least-squares fit.
Cerebral blood volume (CBV), CBF, and mean tran-
sit time (MTT) maps were calculated from DSC data
that were converted to concentration changes over time
curves and deconvolved with an automatically selected
arterial input function.16,17
Volumetric image analysis. WMH lesions were outlined
using MRIcro software (University of Nottingham
School of Psychology, Nottingham, UK; www.mricro.
com). Experienced operators blinded to K2 results out-
lined the WMH region on each supratentorial FLAIR
slice and saved the outline as a region of interest (ROI).
Another whole-brain WMH ROI was created by set-
ting a threshold that matched the supratentorial WMH
ROI intensity. The intersection between these two ROIs
was manually edited to produce the final WMH ROI,
and WMHv was generated for each subject. To reduce
confounds from hyperintensity due to acute infarction,
analysis was limited to the contralesional hemisphere.
Scans with bilateral acute infarcts were excluded
from analysis. DWI and FLAIR sequences were
cross-referenced to ensure the exclusion of T2-
hyperintense signal due to edema, chronic infarcts, or
acute ischemia.
Volumes of perfusion deficits measured on ipsilateral
MTT maps (MTTv) and DWI lesion volumes (DWIv)
were calculated semi-automatically, using MRIcro soft-
ware. Intensity threshold-based method used for
WMHv calculation (see above) was adopted for the
purpose of DWIv and MTTv calculation. ADC maps
were cross-referenced against DWI maps to ensure
exclusion of subacute and chronic T2-hyperintense
lesions. All images were analyzed by trained research
staff (S.L., H.L., L.C., A.L., H.H.K., M.R.E., N.S.R.),
each of whom received standardized instruction and
tested against a ‘‘gold standard’’ set (n¼ 10) with
inter-rater correlation coefficient 0.92–0.95 prior to
deriving volumetric data for this dataset. All readers
were blinded to K2 results, clinical characteristics,
and outcome data.
Normal-appearing white matter analysis. DWI, PWI and
FLAIR datasets were co-registered to one another
using semi-automated co-registration software (MNI
Autoreg18) and to the ICBM-452 T1 5th Order
Polynomial Warps Atlas.19 Using the ICBM probabil-
istic atlas,20,21 white matter masks were created using
a threshold of 95% probability. NAWM was seg-
mented from the hemisphere contralateral to the
acute infarct by subtracting the WMH ROI from
white matter masks. To minimize inclusion of abnor-
mal tissue in NAWM masks, the WMH ROIs were first
dilated successively three times (mincmorph22) prior to
subtraction, and NAWM masks limited to tissue with
ADC values less than 1200 106mm2/s (Figure 1).
The mean K2 coefficients and ADC were measured in
the NAWM.
Outcome definitions
Functional outcome was measured as modified Rankin
scale score (mRS) at 90 days after AIS, obtained either
by in-person interview, or using a validated telephone-
based approach.23 Outcome was considered favorable
in patients with 90-day mRS< 2.
Hemorrhagic transformation (HT) was defined as
presence of hemorrhagic infarction (petechial hemor-
rhage) or parenchymal hematoma on imaging completed
within 48h of LKW (T2* MRI sequence, or non-
contrast head CT) based on European Collaborative
Acute Stroke Study (ECASS) criteria.24
Statistical analysis
All variables were reported as either a mean value
(	standard deviation [SD]), a median value with an
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interquartile range (IQR), or a proportion/percentage
of total. Lesion volumes and MMP-2 values were log-
transformed for all regression analyses. Univariable
analysis was performed using Wilcoxon two-sample
rank sum test for nominal variables, Spearman’s corre-
lation coefficient for ordinal or continuous variables
and logistic regression for binary responses, as appro-
priate. Variables that showed a P-value of <0.10
in univariable analysis were used in multivariable
linear regression implemented with backward stepwise
regression. The selected variables to include in the
final model are based on the Akaike Information
Criterion (AIC), a measure that is a function of both
training error and complexity.25 Statistical analyses
were performed using JMP Pro 12.2.0 (SAS Institute,
Middleton, MA).
Results
One hundred eighty-four AIS subjects met our inclu-
sion criteria (Table 1). Sixty-five patients (35%)
received thrombolytic treatment, of which 64 patients
received intravenous tissue plasminogen activator
(IV tPA) only, and 1 patient underwent combined treat-
ment (IV tPA plus intra-arterial treatment). Patients
treated with thrombolytic therapy (N¼ 65) exhibited
significantly larger acute DWI volumes (13.2 [2.5–
37.8] cm3 vs. 5.7 [1.2–18.9 cm3]; p¼ 0.022) compared
to patients who were not (N¼ 119).
In univariable analysis, mean NAWM K2 coeffi-
cients were significantly associated with age, sex, body
mass index (BMI), initial stroke severity as measured
by admission National Institutes of Health Stroke Scale
(NIHSS) score, mean ADC in NAWM, and contrale-
sional WMHv (Tables 2 and 3). In a subset analysis of
the thrombolysis group, we found that women still had
significantly higher K2 coefficients than men
(p¼ 0.0039) despite the smaller number of patients.
However, this was no longer the case for non-thrombo-
lysis group, where no statistically significant difference
was found (p¼ 0.23). Correlation analysis among the
thrombolysis group showed no significant correlation
between K2 and the variables in Table 3. The opposite
was true for the non-thrombolysis group, resulting in
significant correlations for DWIv (r¼ 0.24, p¼ 0.0078),
MTTv (r¼ 0.28, p¼ 0.0024), contralateral WMHv,
(r¼ 0.24, p¼ 0.0081), ADC (r¼ 0.29, p¼ 0.0017), age
(r¼ 0.35, p< 0.0001), NIHSS (r¼ 0.34, p¼ 0.0011),
and baseline MMP-2 levels (r¼ 0.20, p¼ 0.0027).
Higher mean ADC in NAWM was significantly
associated with hypertension (HTN), atrial fibrillation
(AF), coronary artery disease (CAD), as well as age,
systolic blood pressure (SBP), NIHSS, and K2 coeffi-
cients in NAWM (Tables 2 and 3). Both mean K2 and
ADC in NAWM were correlated with elevated levels of
MMP-2 at baseline, and mean ADC was correlated
with MMP-2 levels at 48 h. MMP-2 levels at baseline
(Spearman’s r¼ 0.31, p< 0.0001) and at 48 h
Figure 1. Neuroimaging characteristics of diffuse microvascular dysfunction in a patient with acute ischemic stroke. Top row (panel a–e)
demonstrates an example of the normal-appearing white matter region-of-interest in a patient with acute ischemic stroke and white
matter hyperintensity volume of 2.36 cm3. (a) FLAIR image, (b) manual WMH outline (red), (c) dilated WMH outline (blueþ red),
(d) co-registered white matter probability mask, (e) contralesional normal appearing white matter mask (green) calculated as voxels with
probability >95% of being white matter AND not in dilated mask (c). Bottom row (panel f–k) demonstrates this patient’s acute (f) DWI,
(g) ADC, (h) CBF, (i) CBV, (j) MTT, and (k) K2 map shown overlaid on the FLAIR scan (for clarity only the contralateral hemisphere values
are shown). All images are displayed in radiologic format.
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(Spearman’s r¼ 0.23, p¼ 0.0072) were significantly
correlated with WMHv. Subset analyses as a function
of thrombolysis found results similar to the entire
cohort with the exception of CAD, which were no
longer significant, most likely due to reduced sample
size. For the thrombolysis group, correlation analysis
produced similar results, except for SBP, NIHSS and
48-h MMP-2 levels were no longer significantly corre-
lated with ADC values. In contrast for the non-throm-
bolysis group, only SBP was no longer significantly
correlated with mean ADC. Contralesional WMHv
was an independent predictor of both mean K2 (b
411, p¼ 0.0007) and ADC (b 9.5, p¼ 0.0056) in
NAWM.
Acute cerebral tissue injury
Acute DWIv and MTTv were correlated with mean
NAWM K2 (DWIv Spearman’s r 0.15, p¼ 0.04 and
MTTv Spearman’s r 0.21, p¼ 0.0035), but not with
mean ADC values in NAWM (Table 3).
Hemorrhagic transformation
Patients who experienced HT had higher K2 coeffi-
cients than those who did not (1092	 1143 vs.
729	 2066, p¼ 0.02). In addition, treating HT as an
ordinal variable (none¼ 0, hemorrhagic infarction¼ 1,
parenchymal hematoma¼ 2), found a significant correl-
ation between more severe HT and increasing K2
(Spearman’s r 0.18, p¼ 0.017). In contrast, there was
no difference in mean ADC values between patients
with and without HT (793	 59 vs. 800	 59, p¼ 0.59),
nor significant correlation with HT severity
(Spearman’s r 0.05, p¼ 0.49). The only independent
predictor of HT was DWIv (b 0.35, p¼ 0.0027).
Functional outcomes after stroke
Long-term functional outcome after stroke was asso-
ciated with MRI markers of acute and chronic cerebro-
vascular injury (Table 4). Mean NAWMK2 coefficients
(Spearman’s r 0.16, p¼ 0.04) and mean NAWM ADC
values (Spearman’s r 0.40, p< 0.0001) were correlated
with 90-day mRS. Patients with unfavorable outcomes
(mRS 2) had greater BBB permeability in NAWM
(1145	 2574 vs. 615	 1658 106, p¼ 0.03) and
higher mean diffusivity values (816	 64 vs. 777	 46
106mm2/s, p< 0.0001). Similarly, elevated levels of
MMP-2 at baseline were associated with worse long-
term outcome (Spearman’s r 0.17, p¼ 0.037).
In a univariable analysis, admission NIHSS, contrale-
sional ADC, and linear-log transformed DWIv (all
p< 0.0001), linear-log transformed MTTv (p¼ 0.0002),
use of thrombolysis (p¼ 0.002); age (p¼ 0.0003);
Table 1. Clinical characteristics of the study population.
Demographics and risk factors N¼ 184
Age, mean	 SD 68	 15
Female sex, n (%) 79 (43)
Caucasian, n (%) 177 (96)







Creatinine, mean	 SD, mg/dL 1.04	 0.29
Body mass index,c kg/m2 28.1	 6.0
Admission NIHSS, median (IQR), points 5 (3–12)
Hypertension, n (%)a 129 (70)
Diabetes, n (%) 38 (21)
Atrial fibrillation, n (%) 50 (27)
Coronary artery disease, n (%) 44 (24)
Hyperlipidemia, n (%) 82 (45)
Prior stroke, n (%) 36 (20)
Smoking (current or past), n (%) 120 (65)
Thrombolytic treatment, n (%) 65 (35)
MMP-2 (Baseline), median [IQR], ng/mL 305 [238–370]
MMP-2 (48 h),d median [IQR], ng/mL 271 [220–338]
CCS classification,b n (%)
Cardioembolic 94 (51)
Large artery atherosclerosis 39 (21)
Small vessel disease 9 (5)
Other 8 (4)
Undetermined 33 (18)
Hemorrhagic transformation,e n (%)
None 134 (77)
Parenchymal hematoma 16 (9)
Hemorrhagic infarction 24 (14)
Infarct volume (DWI), median [IQR], cm3 7.4 [1.3–22.7]






K2 coefficients (106) in NAWM,
mean	 SD, s1
836	 2019
ADC (106) in NAWM,
mean	 SD, mm2/s
797	 59
90-day mRS,f median [IQR] 1 [1–3]
Favorable outcome (90-day mRS< 2),f n (%) 84 (54)
aN¼ 181; bN¼ 183; cN¼ 164; dN¼ 139; eN¼ 174; fN¼ 156.
ADC: apparent diffusion coefficient; CCS: Causative Classification of
Stroke; DWI: diffusion-weighted imaging; IQR: interquartile range;
MMP-2: matrix metalloproteinase-2; mRS: modified Rankin Scale score;
MTT: mean transit time; WMHV: white matter hyperintensity volume;
NAWM: normal-appearing white matter; NIHSS: National Institutes of
Health Stroke Scale; SD: standard deviation; WMH: white matter
hyperintensity.
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linear-log transformed WMHv (p¼0.006); AF
(p¼ 0.01); linear-log transformed baseline MMP-2
levels (p¼ 0.037); and K2 values (p¼ 0.04) were asso-
ciated with 90-day mRS score, but not gender, race,
ethnicity, etiological stroke subtype, admission SBP
or diastolic blood pressure (DBP), BMI, HT, or
linear-log transformed 48-h MMP-2 levels, or history
of HTN, hyperlipidemia (HL), diabetes mellitus (DM),
Table 2. Comparison of mean K2 coefficients and mean ADC values in normal appearing white matter between patients with clinical
characteristic present and those without.
Mean K2 coefficient (106) (	SD) in NAWM Mean ADC (106) (	SD) in NAWM
Characteristic present? (Y/N) Characteristic present? (Y/N)
Yes No P Yes No P
Female 1027	 1193 693	 2461 0.0062 804	 69 792	 49 0.19
Caucasian 811	 2015 1468	 2166 0.82 797	 59 786	 30 0.76
Hispanic 1042	 952 830	 2071 0.58 778	 57 798	 59 0.34
Hypertension 753	 1712 1032	 2609 0.98 806	 59 776	 52 0.0005
Diabetes 1076	 2153 774	 1985 0.71 805	 57 795	 59 0.28
Atrial fibrillation 787	 2137 855	 1981 0.35 828	 62 785	 53 <0.0001
Coronary artery disease 1012	 1392 781	 2180 0.57 815	 68 792	 54 0.037
Hyperlipidemia 1017	 2141 691	 1913 0.65 800	 51 794	 64 0.43
Prior stroke 1307	 2570 722	 1853 0.08 807	 62 795	 58 0.14
Smoking 940	 2184 642	 1665 0.87 794	 52 802	 69 0.99
Thrombolytic treatment 640	 1953 944	 2054 0.63 798	 55 796	 61 0.50
CCS classification 0.74a 0.084a
Cardioembolic 921	 2237 – 806	 68 –
Large artery Atherosclerosis 881	 1924 – 778	 39 –
Small vessel disease 746	 1276 – 816	 54 –
Other 1388	 1285 – 779	 54 –
Undetermined 450	 1825 – 793	 45 –
aTested with analysis of variance.
CCS: causative classification of stroke; mRS: modified Rankin Scale score; SD: standard deviation.
Table 3. Correlation between continuous clinical characteristics and mean K2 coefficients and mean ADC
values in normal appearing white matter.
Mean K2 coefficients (106) in NAWM Mean ADC (106) in NAWM
Spearman’s coefficient P Spearman’s coefficient P
DWI lesion volume 0.15 0.04 0.03 0.72
MTT lesion volume 0.21 0.0035 0.049 0.51
Contralateral WMH volume 0.19 0.010 0.51 <0.0001
Mean ADC in NAWM 0.23 0.0014 – –
Age 0.26 0.0004 0.61 <0.0001
Systolic blood pressure 0.004 0.96 0.17 0.024
Diastolic blood pressure 0.10 0.17 0.05 0.47
Creatinine 0.067 0.37 0.089 0.23
Body mass index 0.21 0.0064 0.054 0.52
NIHSS score 0.19 0.0099 0.21 0.0043
MMP-2 (Baseline), ng/mL 0.17 0.022 0.37 <0.0001
MMP-2 (48 h), ng/mL 0.084 0.32 0.32 0.0001
ADC: apparent diffusion coefficient; DWI: diffusion-weighted imaging; IQR: interquartile range; MMP-2: matrix metallo-
proteinase 2; mRS: modified Rankin Scale score; MTT: mean transit time; NAWM: normal-appearing white matter;
NIHSS: National Institutes of Health Stroke Scale; SD: standard deviation; WMH: white matter hyperintensity.
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CAD, or prior stroke (all p> 0.05). A backward step-
wise analysis of all variables with univariate p-value
<0.10 [including NIHSS, ADC, ln DWIv, ln MTTv,
thrombolysis, age, ln WMHv, AF, baseline MMP-2,
K2, prior stroke (p¼ 0.06), and BMI (p¼ 0.06)] was
carried out in association with (a) 90-day mRS score
and (b) favorable outcome (mRS< 2).
From the multivariable regression analysis of 90-day
mRS, initial stroke severity (as measured by admission
NIHSS score), history of prior stroke, and loss of
microstructural integrity of white matter in contrale-
sional NAWM, as measured by ADC, emerged as inde-
pendent predictors of long-term functional outcome
after AIS (Table 5).
Discussion
In this study, we report that in patients with AIS,
increased BBB permeability is associated with (a) loss
of microstructural NAWM integrity and (b) acute cere-
bral tissue and long-term functional outcomes. Our
data demonstrate that post-stroke outcomes are less
favorable in patients with pre-existing chronic micro-
vascular dysfunction, as manifested by diffusely
increased BBB permeability and loss of microstructural
white matter integrity measured with perfusion- and
diffusion-weighted MRI, respectively. This diffuse
injury is detectable in the hemisphere putatively unaf-
fected by acute ischemia, in the white matter that
appears to be otherwise normal in conventional
T2-weighted FLAIR images. This finding may help
provide a pathophysiologic explanation for the long-
observed association between pre-stroke functional
status and post-stroke functional outcome.26–28
Our results also identify elevated NAWM diffusivity
and increased BBB permeability as imaging biomarkers
that may be useful in providing individualized, patient-
specific assessments of the effects of long-term vascular
risk factor exposure, which has previously been linked
to worse post-stroke outcomes.
Our study shows that WMH burden is an independ-
ent predictor of mean K2 coefficients in NAWM, a
measure of diffuse BBB permeability. These data cor-
roborate a recently reported increase in ‘‘BBB leakage’’
in patients with SVD,29 and support the hypothesis that
diffuse cerebral microvascular dysfunction is a common
disease mechanism leading to both diffuse loss of BBB
integrity and focal white matter lesions. We tested this
hypothesis in a cohort of AIS patients undergoing acute
clinical MRI with PWI, a population that is uniquely
suited for this experiment, given their appreciable
burden of WMH30 and availability of a measurable
outcome after an acute event. To avoid confounding
by acute ischemic changes on MRI, we extracted the
BBB permeability metrics from NAWM, and measured
WMHv in the hemisphere contralateral to acute infarct.
The association between NAWM K2 coefficients and
WMHv in the contralesional hemisphere implies that
the ‘‘leaky’’ BBB may, at least in part, contribute to
pre-existing burden of leukoaraiosis, as suggested in a
number of prior reports.8,31,32
We further validated this observation by testing the
association between K2 coefficients and plasma levels
of MMP-2, an enzyme widely regarded as contributory
to chronic BBB remodeling, as a potential biological
mechanism underlying diffuse cerebrovascular endothe-
lial dysfunction, increased BBB permeability, and lead-
ing to microangiopathic white matter changes.33,34
We observed a modest, albeit statistically significant
correlation between mean K2 coefficients in NAWM
and plasma MMP-2 levels within 9 h of LKW time,
suggesting that this MMP-2 elevation reflects a chronic
microangiopathic process injurious to white matter,
Table 4. Correlation of imaging markers of acute and chronic
cerebrovascular injury with clinical outcomes.

















ADC: apparent diffusion coefficient; DWI: diffusion-weighted imaging;
mRS: modified Rankin Scale score; MTT: mean transit time; NAWM:
normal-appearing white matter; WMH: white matter hyperintensity.
Table 5. Final predictors of 90-day functional outcome in 156




Admission NIHSS 0.13 <0.0001
ADC in NAWM 0.0059 0.002
Thrombolytic treatment (yes) 0.18 0.082
Prior stroke (no) 0.35 0.0039
Age 0.013 0.068
ADC: apparent diffusion coefficient; NAWM: normal-appearing white
matter; NIHSS: National Institutes of Health Stroke scale score; mRS:
modified Rankin Scale score; TPA: tissue plasminogen activator.
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consistent with our findings reported in a larger
cohort.12 While other confounders related to stroke
severity, stroke subtype, pre-existing and acute co-
morbidities, as well as medical interventions for
stroke in the hyperacute phase might alter circulating
levels of biomarkers,35,36 and consequently, limit their
utility in AIS, further studies of MMP-2 as a potential
link to the ‘‘leaky BBB’’ and diseased white matter are
warranted. MMP-2 has been extensively studied as a
potential biomarker of many disorders including
acute myocardial infarction,35 although data are lim-
ited with regard to MMP-2 levels in acute stroke
patients vs. non-stroke controls.36 However, these stu-
dies of stroke and MMP-2 did not take into account
severity of WMH, nor was the stroke-free status of
controls verified using MRI. While we are unable to
compare our results with the prior data directly, both
baseline and 48-h MMP-2 levels in our AIS cohort were
within the previously published range. Overall, this
novel association between WMH burden and MMP-2
levels in AIS requires future study.
Another piece of evidence regarding the link between
BBB permeability and white matter disease in our study
is correlation, albeit modest, between NAWM K2 coef-
ficients and ADC values, which is often interpreted as
MRI markers of diffuse white matter structural integ-
rity. A number of prior studies found that microstruc-
tural changes in NAWM precede macrostructural
changes, that are ultimately visualized on T2 FLAIR
MRI as WMH.37,29 Using ADC to estimate diffusivity
of the water molecules along white matter tracts allows
us to quantify the degree of structural integrity of
NAWM, which is known to represent the total
burden of white matter disease in the brain exposed
to long-term vascular risk factors.38 In our study,
mean K2 coefficients correlated positively with the
elevated values of ADC in NAWM, implying that the
BBB permeability is associated with greater microstruc-
tural damage of the white matter, and as such, serving
as a marker of a potential underlying mechanism of
disease that links cerebral microvascular dysfunction
and WMH. Furthermore, despite its ‘‘normal appear-
ance’’ on T2 FLAIR MRI, NAWM in patients with
ischemic stroke might demonstrate early, albeit subclin-
ical, changes that contribute to the overall burden of
white matter injury due to diffuse microvascular
changes and related disability.39,40
Whereas WMH severity was a strong predictor of
both K2 and ADC values in NAWM, they correlated
with different vascular risk factors. Higher mean
NAWM K2 values were associated with age, female
sex, and lower BMI, and mean ADC values in contrale-
sional NAWM were associated with age, increased
admission SBP and history of HTN, as well as CAD
and AF. The differences between the vascular risk
profiles associated with NAWM K2 and ADC may
highlight the distinct aspects of cerebrovascular disease
captured by these imaging parameters and, possibly,
point at the contributing mechanisms of disease.
Specifically, microstructural integrity of the NAWM,
as reflected in mean ADC, might be affected by
life-long exposure to the common cardiovascular risk
factors (HTN, CAD, AF) and is subject to their related
pathophysiology.29,41,42 However, the disease biology
related to female sex-specific factors and relationship
with BMI (i.e., the ‘‘obesity paradox’’) in developing
greater BBB permeability is likely more complex and
requires further study.43,44 The role of age in these dis-
ease processes remains to be fully understood; however,
being the most important determinant of WMHv
across any population ever studied, age was the only
other predictor of mean NAWM ADC independent of
WMHv in this cohort, implying that its role varies in
cerebrovascular disease biology.29 In addition, thromb-
olysis appeared to affect K2 coefficients more so than
ADC. Females had significantly higher K2 coefficients
than males only in the thrombolysis group, but not the
non-thrombolysis group, despite smaller cohort size.
In addition, in correlation analysis, many of the vari-
ables in Table 3 were no longer significantly correlated
with K2 coefficients in the thrombolysis group. These
results likely suggest an interaction between thromboly-
sis and BBB permeability, which is known to occur.
Finally, we report that the MRI metrics of micro-
vascular dysfunction are associated with variables
reflective of stroke severity, as well as ischemic tissue
and clinical outcomes. In our study, elevated NAWM
K2 and ADC values are correlated with higher admis-
sion NIHSS and worse functional outcomes at 90 days
post-stroke. Furthermore, higher BBB permeability in
NAWM was associated with greater DWI lesion size,
increased volume of MTT perfusion deficit, and greater
risk of HT at 48-h post-stroke. These data suggest that
the pre-existing subclinical white matter injury may
play a significant role in the brain microvascular com-
pensatory capacity and susceptibility to acute ischemia.
Diffusely increased permeability of the BBB may reflect
up-regulation of pro-inflammatory cascade, increasing
oxidative stress, and limited capacity of the brain tissue
to counteract the effects of acute ischemia.1–3 Because
these chronic BBB changes are diffuse, acute-on-
chronic injury during AIS in the affected area results
in relatively larger infarct volumes and higher rate of
HT of acutely infarcted tissue. The association of ele-
vated NAWM K2 and ADC values with higher NIHSS
may also suggest the role of pre-existing white matter
integrity in mechanisms of early recovery during AIS.2
Similarly, our findings uncover a correlation between
unfavorable post-stroke functional outcome and the
growing burden of cerebral white matter damage
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accounted for by the (a) total volume of WMH, (b)
microstructural injury as estimated by elevated mean
diffusivity in NAWM, and (c) diffuse increase in the
BBB permeability signaling endothelial dysfunction of
the small cerebral vasculature. In this context, BBB dis-
ruption might appear as a tentative biological target for
novel therapies aimed at mitigating brain injury and
improving functional recovery after acute stroke.
This study has a number of important limitations.
First, the retrospective study design and missing data
points for several variables (including 28 missing points
for 90-day mRS, 10 for HT, 19 for BMI, and 45 for
48-h MMP-2 levels) might have led to diminished stat-
istical power of this analysis to demonstrate the extent
of association with the MRI characteristics. As a result,
the variables with missing data elements might have
failed to emerge as independent predictors in multivari-
able models. This limitation is also important in con-
sideration of potential confounders, such as reperfusion
status after thrombolytic treatment or precise duration
of stroke symptoms (time from LKW to MRI), which
are not available in our dataset but could be related to
imaging characteristics or clinical outcomes in this
patient population. Secondly, a potential selection
bias might exist in the hospital-based studies of AIS
subjects with lower stroke severity and higher propor-
tion of favorable outcomes, such as ours. However, this
type of bias would underestimate the effect of associ-
ation between the MRI measures and the metrics of
outcome, including in multivariable models, i.e.
increasing the chance of type II error. Third, this
study is limited to AIS patients who underwent MRI
with PWI within 9 h of LKW, and while the character-
istics of our overall AIS cohort are consistent with
those of average hospital-based AIS studies, we
acknowledge that MRI-based studies are more likely
to miss patients with milder (unrecognized) or more
severe (too sick to undergo an MRI) stroke syndromes.
A related limitation is the lack of baseline MRI data on
the patients presenting with AIS and consequently, a
question remaining as to whether acute ischemia may
directly impact MRI measurements, such as mean K2
coefficient and ADC values. A recent study indicated
that, at least, transient elevation of BBB permeability
can be seen in the brain regions contralesional to acute
stroke.45 While findings of increased permeability in
that report were limited by assessment of only a
‘‘mirror’’ stroke lesion ROI and inclusion of both
grey and white matter permeability estimates in their
analysis, a possibility of global BBB changes in the
setting of acute ischemia warrants further consider-
ation. Nevertheless, a transient global increase in BBB
permeability during AIS does not explain the associ-
ation between the degree of BBB leakiness and WMH
burden, nor does it explain the link between WMH and
diffusivity metrics we observe in our dataset. Even if the
BBB change is transient, our results suggest that
patients with larger WMH burden are more likely to
show greater increase in BBB permeability due to
an already diffusely compromised microvasculature.
Furthermore, our data align with the prior reports of
association between the leaky BBB and loss of micro-
structural NAWM integrity in non-AIS subjects.14
Prospective studies aiming to assess the MRI charac-
teristics of WM integrity in stroke-free individuals,
AIS patients, and convalescent stroke survivors could
clarify this issue, and until then, current data should be
interpreted with caution.
Another potential limitation is limited sensitivity of
DSC perfusion imaging-derived K2 coefficients in mea-
suring BBB changes, particularly in the setting of
delayed bolus arrival and/or decreased blood flow.
In fact, K2 coefficients in normal brain tissue such as
NAWM are expected to be very low, as in our clinical
dataset (mean NAWM K2 of 836 106 s1). In add-
ition, there are limited studies in regards to the repro-
ducibility and repeatability of K2 values across patients
and across scanners, as exists for other techniques that
measure BBB permeability, such as dynamic contrast
enhanced MRI (DCE) which measures Ktrans. There
have been studies showing good repeatability of cor-
rected CBV maps (which are based on K2 data).46
In addition, there has been a study which showed
good correlation between Ktrans and K2.47 Clearly
more research focused on the repeatability and repro-
ducibility of K2 is needed. Some previous studies29,45
have utilized DCE rather than DSC perfusion imaging,
thereby possibly detecting changes in BBB permeability
more accurately. However, DCE in the brain typically
requires very long acquisition times (>20min), which
are not practical in acute stroke settings. MR perfusion
imaging used in the context of clinical management of
AIS patients typically includes DSC PWI based on its
relatively short acquisition time, thereby rendering
DCE imaging of limited use in the AIS clinical scenario.
In addition, DSC is susceptible to a number of arti-
facts such as changes in T1 or T2, which may be pre-
sent in stroke patients and which may lead to
incorrect estimates of permeability. However, clinical
MRI protocols used in AIS evaluation are extremely
time-sensitive, and as a result, T1 and T2 mapping
that may lead to more accurate characterization of
permeability is typically not done in this patient popu-
lation due to the extra time currently required to
acquire this data. By limiting our analysis to the con-
tralesional hemisphere, we sought to minimize poten-
tial confounds from delayed flow as well as from
ischemic effects from the index stroke on K2 meas-
ures. Despite the limitations of DSC use for assess-
ment of vascular permeability, we were able to
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demonstrate associations between K2 coefficients and
WMH burden, as well as functional outcome after
stroke. This suggests that a pragmatic approach to
BBB permeability measurement could include analysis
of the DSC perfusion imaging.
A major strength of our study is inclusion of the
largest-to-date cohort of AIS subjects with comprehen-
sive, quantitative characterization of the NAWM using
diffusion- and perfusion-derived metrics. In addition,
we tested the potential role of MMP-2 as a biomarker
of chronic BBB remodeling in association with MRI
characteristics, as well as clinical and neuroimaging
assessment of post-stroke outcomes. All MRI and
laboratory variables in this analysis were collected by
investigators blinded to clinical outcome, and the study
was completed using standardized approach to data col-
lection and quality control, as per SPOTRIAS criteria.12
In summary, our findings indicate that increased BBB
permeability in NAWM of the contralesional hemi-
sphere is associated with loss of white matter structural
integrity and post-stroke outcomes. Furthermore, diffu-
sivity metrics in NAWM are strongly associated with
WMHv, which is consistent with its role as a marker
of microstructural white matter disarray, likely related
to dysregulation of chronic BBB remodeling, as evi-
denced by elevated MMP-2 levels. In the future, measur-
ing these diffuse microangiopathic changes on MRI in
patients with AIS may improve prediction of cerebral
tissue and functional post-stroke outcomes.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: This work was supported by the National Institutes of
Health NINDS Specialized Program of Transitional Research
in Acute Stroke (SPOTRIAS) grant P50-NS051343 (Furie
PI); R01NS082285 (SALVO study, Rost PI); R01NS086905
(Rost, PI); R01NS059775 (Wu, PI); R01NS086905 (Wu, PI).
Natalia Rost is supported in part by NIH-NINDS R01
NS082285 & NS086905. Pedro Cougo was supported by
NIH 5P50NS051343. Svetlana Lorenzano was supported
by NIH 5P50NS051343. Hua Li was supported by NIH
5P50NS051343. Steven K Feske was supported by
NIH 5P50NS051343. Karen L Furie was supported by NIH
5P50NS051343. Ona Wu is supported in part by NIH-
NINDS P50NS051343, R01NS059775 and R01NS063925,
R01 NS082285 & NS086905. She is the co-inventor of a
patent on ‘‘Delay-compensated calculation of tissue blood
flow,’’ US Patent 7,512,435, 31 March 2009, and the patent
has been licensed to General Electric, Siemens, Imaging
Biometrics and Olea Medical.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of this
article.
Authors’ contributions
Natalia S Rost: study concept/design, study supervision, data
acquisition, interpretation of data, drafting/revising the
manuscript for intellectual content
Pedro Cougo: study design, data acquisition, statistical ana-
lysis/interpretation of data, drafting/revising the manuscript
for intellectual content.
Svetlana Lorenzano: data acquisition, interpretation of data,
drafting/revising the manuscript for intellectual content
Hua Li: data acquisition, revising the manuscript for intellec-
tual content.
Lisa Cloonan: data acquisition, revising the manuscript for
intellectual content.
Mark JR Bouts: data acquisition, revising the manuscript for
intellectual content.
Arne Lauer: data acquisition, revising the manuscript for
intellectual content.
Mark R Etherton: data acquisition, revising the manuscript
for intellectual content.
Hasan H Karadeli: data acquisition, revising the manuscript
for intellectual content.
Patricia L Musolino: interpretation of data, revising the
manuscript for intellectual content.
William A Copen: interpretation of data, revising the manu-
script for intellectual content.
Ken Arai: data acquisition, revising the manuscript for intel-
lectual content.
Eng H Lo: data acquisition, revising the manuscript for intel-
lectual content.
Steven K Feske: study design, study supervision, revising the
manuscript for intellectual content.
Karen L Furie: study design, study supervision, revising the
manuscript for intellectual content.
Ona Wu: study concept and design, data acquisition, data
analysis and interpretation of data, drafting/revising the
manuscript for intellectual content.
References
1. Ay H, Arsava EM, Rosand J, et al. Severity of leukoar-
aiosis and susceptibility to infarct growth in acute stroke.
Stroke 2008; 39: 1409–1413.
2. Rost NS, Fitzpatrick K, Biffi A, Kanakis A, et al. White
matter hyperintensity burden and susceptibility to cerebral
ischemia. Stroke 2010; 41: 2807–2811.
3. Arsava EM, Rahman R, Rosand J, et al. Severity of leu-
koaraiosis correlates with clinical outcome after ischemic
stroke. Neurology 2009; 72: 1403–1410.
4. Pantoni L and Garcia JH. Pathogenesis of leukoaraiosis: a
review. Stroke 1997; 28: 652–659.
5. O’Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of
cerebral blood flow reduction in patients with ischemic
leukoaraiosis. Neurology 2002; 59: 321–326.
6. Isaka Y, Okamoto M, Ashida K, et al. Decreased cerebro-
vascular dilatory capacity in subjects with asymptomatic
periventricular hyperintensities. Stroke 1994; 25: 375–381.
7. Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood
flow in small vessel disease: a systematic review and meta-
analysis. J Cereb Blood Flow Metab 2016; 36: 1653–1667.
84 Journal of Cerebral Blood Flow & Metabolism 38(1)
8. Wardlaw JM, Doubal FN, Valdes-Hernandez M, et al.
Blood-brain barrier permeability and long-term clinical
and imaging outcomes in cerebral small vessel disease.
Stroke 2013; 44: 525–527.
9. Wardlaw JM, Sandercock PA, Dennis MS, et al. Is
breakdown of the blood-brain barrier responsible for
lacunar stroke, leukoaraiosis, and dementia? Stroke
2003; 34: 806–812.
10. Chen C, Ostrowski RP, Zhou C, et al. Suppression of
hypoxia-inducible factor-1alpha and its downstream
genes reduces acute hyperglycemia-enhanced hemor-
rhagic transformation in a rat model of cerebral ischemia.
J Neurosci Res 2010; 88: 2046–2055.
11. Jalal FY, Yang Y, Thompson JF, et al. Hypoxia-induced
neuroinflammatory white-matter injury reduced by mino-
cycline in shr/sp. J Cereb Blood Flow Metab 2015; 35:
1145–1153.
12. Corbin ZA, Rost NS, Lorenzano S, et al. White matter
hyperintensity volume correlates with matrix metallopro-
teinase-2 in acute ischemic stroke. J Stroke Cerebrovasc
Dis 2014; 23: 1300–1306.
13. Boxerman JL, Schmainda KM and Weisskoff RM.
Relative cerebral blood volume maps corrected for con-
trast agent extravasation significantly correlate with
glioma tumor grade, whereas uncorrected maps do not.
AJNR 2006; 27: 859–867.
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